公开(公告)号：US20130158104A1

公开(公告)日：2013-06-20

申请号：US13703179

申请日：2011-06-10

Applicant: Fátima Bosch Tubert ,  Éduard Ayuso López ,  Albert Ruzo Matías

Inventor： Fátima Bosch Tubert ,  Éduard Ayuso López ,  Albert Ruzo Matías

IPC: A61K48/00 ,  C12N15/864 ,  C12N15/52

CPC classification number: C12N15/86 ,  A61K48/00 ,  A61K48/0066 ,  C12N9/14 ,  C12N15/52 ,  C12N15/8645 ,  C12N2750/14143 ,  C12N2830/008 ,  C12N2830/48 ,  C12N2840/105

Abstract: The present invention provides new sequences, gene constructions, vectors and pharmaceutical compositions for the treatment of diseases and specially, for the treatment of mucopolysaccharidoses.

公开(公告)号：US20130158033A1

公开(公告)日：2013-06-20

申请号：US13814148

申请日：2011-08-02

Applicant: José Miguel Vela Hernández ,  Daniel Zamanillo-Castanedo ,  Margarita Puig Riera de Conias

Inventor： José Miguel Vela Hernández ,  Daniel Zamanillo-Castanedo ,  Margarita Puig Riera de Conias

IPC: A61K31/5377

CPC classification number: A61K31/5377 ,  A61K31/415 ,  A61K31/4155

Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.

Abstract translation: 本发明涉及使用Sigma配体，特别是式（I）的Sigma配体来预防和/或治疗与阿片类药物治疗相关的阿片样物质诱导的痛觉过敏（OIH）。

公开(公告)号：US20130109659A1

公开(公告)日：2013-05-02

申请号：US13701192

申请日：2011-06-03

Applicant: Luis Soler Ranzani ,  Albert Falivene Aldea

Inventor： Luis Soler Ranzani ,  Albert Falivene Aldea

IPC: A61K47/34 ,  A61K47/32

CPC classification number: A61K47/34 ,  A61K9/2018 ,  A61K9/2027 ,  A61K31/045 ,  A61K31/05 ,  A61K31/135 ,  A61K31/18 ,  A61K31/415 ,  A61K31/4162 ,  A61K31/63 ,  A61K47/32 ,  A61K2300/00

Abstract: The present invention relates to oral pharmaceutical compositions comprising co-crystals of tramadol and celecoxib and processes for the preparation of these oral pharmaceutical compositions. The present invention also relates to methods of using oral pharmaceutical compositions comprising co-crystals of tramadol and celecoxib as medicaments, more particularly for the treatment of pain.

Abstract translation: 本发明涉及包含曲马多和塞来昔布的共晶体的口服药物组合物和制备这些口服药物组合物的方法。 本发明还涉及使用包含曲马多和塞来昔布的共晶的口服药物组合物作为药物的方法，更特别是用于治疗疼痛。

公开(公告)号：US08372990B2

公开(公告)日：2013-02-12

申请号：US12226559

申请日：2007-04-30

Applicant: Miguel Angel Pericas-Brondo ,  Antonio Torrens-Jover ,  Susana Yenes-Minguez ,  Félix Cuevas Cordobés ,  Carmen Garcia Granda

Inventor： Miguel Angel Pericas-Brondo ,  Antonio Torrens-Jover ,  Susana Yenes-Minguez ,  Félix Cuevas Cordobés ,  Carmen Garcia Granda

IPC: C07D209/52 ,  A61K31/403 ,  A61P3/06 ,  A61P29/00 ,  A61P1/00 ,  A61P25/28 ,  A61P19/02 ,  A61P9/00 ,  A61P25/30

CPC classification number: A61K31/403 ,  C07D209/52 ,  C07D209/94

Abstract: The present invention relates to substituted bicyclic tetrahydropyrrole compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.

Abstract translation: 本发明涉及通式（I）的取代的双环四氢吡咯化合物，其制备方法，包含这些化合物的药物及其在制备用于治疗人和动物的药物中的用途。

公开(公告)号：US20130028937A1

公开(公告)日：2013-01-31

申请号：US13517910

申请日：2010-12-23

Applicant: Carlos Ramon Plata Salaman ,  Sebastia Videla Ces ,  Nicolas Tesson ,  Montserrat Trilla Castano

Inventor： Carlos Ramon Plata Salaman ,  Sebastia Videla Ces ,  Nicolas Tesson ,  Montserrat Trilla Castano

IPC: A61K31/415 ,  A61P19/02 ,  A61P25/24 ,  A61K9/00 ,  A61P29/00

CPC classification number: C07D231/12 ,  A61K31/137 ,  A61K31/415 ,  C07C217/74 ,  C07C2601/14 ,  A61K2300/00

Abstract: The present invention relates to a co-crystal of celecoxib and venlafaxine, processes for preparation of the same and its use as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain, including chronic pain; or of depression in patients which suffer from chronic pain and/or chronic inflammation or in patients with a chronic musculo-skeletal inflammatory illness, with the inflammatory illness preferably being selected from osteoarthritis or rheumatoid arthritis.

Abstract translation: 本发明涉及塞来昔布和文拉法辛的共晶体，其制备方法及其作为药物或药物制剂的用途，更具体地涉及治疗疼痛，包括慢性疼痛; 或患有慢性疼痛和/或慢性炎症的患者或患有慢性肌肉 - 骨骼炎性疾病的患者中的抑郁症，其中炎症性疾病优选选自骨关节炎或类风湿性关节炎。

公开(公告)号：US08349878B2

公开(公告)日：2013-01-08

申请号：US13229917

申请日：2011-09-12

Applicant: Nadine Jagerovic ,  Jose Maria Cumella-Montanchez ,  Maria Pilar Goya-Laza ,  Alberto Dordal Zueras ,  Maria Rosa Cuberes-Altisent

Inventor： Nadine Jagerovic ,  Jose Maria Cumella-Montanchez ,  Maria Pilar Goya-Laza ,  Alberto Dordal Zueras ,  Maria Rosa Cuberes-Altisent

IPC: A61K31/44 ,  C07D249/00

CPC classification number: C07D249/06

Abstract: The invention relates to the use of compounds having pharmacological activity towards the sigma receptor, and more particularly to 1,2,4-triazole derivatives of formula I to processes of preparation of such compounds and to pharmaceutical compositions comprising them.

Abstract translation: 本发明涉及对σ受体具有药理活性的化合物的用途，更具体地说，涉及式I的1,2,4-三唑衍生物的制备方法以及包含它们的药物组合物。

公开(公告)号：US20120321702A1

公开(公告)日：2012-12-20

申请号：US13169393

申请日：2011-06-27

Applicant: Gregorio José ENCINA GARCIA ,  Zhengguo XU

Inventor： Gregorio José ENCINA GARCIA ,  Zhengguo XU

IPC: A61K31/4439 ,  A61P31/04 ,  A61P1/00 ,  A61P1/04 ,  A61K9/48 ,  A61K9/50

CPC classification number: A61K9/5078 ,  A61K9/5084 ,  A61K31/4439

Abstract: The invention refers to an oral solid pharmaceutical composition comprising a mixture of: (a) pellets comprising lansoprazole or a pharmaceutically acceptable salt thereof being free of alkaline-reacting compounds and (b) pellets comprising lansoprazole or a pharmaceutically acceptable salt thereof together with alkaline-reacting compounds.

Abstract translation: 本发明涉及一种口服固体药物组合物，其包含以下混合物的混合物：（a）包含兰索拉唑或其药学上可接受的盐的不含碱性反应化合物的丸剂和（b）包含兰索拉唑或其药学上可接受的盐以及碱 - 使化合物反应。

公开(公告)号：US20120316336A1

公开(公告)日：2012-12-13

申请号：US13577078

申请日：2011-02-04

Applicant: Ramón Berenguer Maimó ,  Jorge Medrano Rupérez ,  Jordi Benet Buchholz ,  Laura Puig Fernandez ,  Lala Pellejà Puxeu

Inventor： Ramón Berenguer Maimó ,  Jorge Medrano Rupérez ,  Jordi Benet Buchholz ,  Laura Puig Fernandez ,  Lala Pellejà Puxeu

IPC: C07D413/12

CPC classification number: C07D231/22 ,  A61K31/4152 ,  A61K31/4155

Abstract: The present invention relates to polymorphs and solvates of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027), processes for their preparation, and to pharmaceutical compositions comprising them.

Abstract translation: 本发明涉及4- [2 - [[5-甲基-1-（2-萘基）-1H-吡唑-3-基]氧基]乙基]吗啉（P027）的盐酸盐的多晶型物和溶剂合物，方法 用于制备它们以及包含它们的药物组合物。

公开(公告)号：US08329880B2

公开(公告)日：2012-12-11

申请号：US12988922

申请日：2009-04-24

Applicant: Antoni Torrens Jover ,  Jordi Corbera Arjona ,  Maria Rosa Cuberes-Altisent

Inventor： Antoni Torrens Jover ,  Jordi Corbera Arjona ,  Maria Rosa Cuberes-Altisent

IPC: C07D231/22 ,  C07C245/02

CPC classification number: C07D231/20

Abstract: The invention relates to a process for preparing naphthalen-2-yl-pyrazol-3-one intermediates, tautomers, and salts thereof, to novel intermediates, and to the use of the intermediates in the preparation of sigma receptor inhibitors.

Abstract translation: 本发明涉及一种制备萘-2-基 - 吡唑-3-酮中间体，互变异构体及其盐的新中间体的方法，以及中间体在制备σ受体抑制剂中的用途。

公开(公告)号：US08314096B2

公开(公告)日：2012-11-20

申请号：US12703126

申请日：2010-02-09

Applicant: Christian Laggner ,  Maria Rosa Cuberes-Altisent ,  Joerg Holenz ,  Juana Maria Berrocal-Romero ,  Maria Montserrat Contijoch-Llobet

Inventor： Christian Laggner ,  Maria Rosa Cuberes-Altisent ,  Joerg Holenz ,  Juana Maria Berrocal-Romero ,  Maria Montserrat Contijoch-Llobet

IPC: A61K31/4152 ,  A61K31/4155 ,  A61K31/5375 ,  A61K31/5377

CPC classification number: A61K31/415 ,  A61K31/4178 ,  A61K31/437 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541

Abstract: The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.